KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) EBITDA (2016 - 2025)

Historic EBITDA for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $8.0 billion.

  • Eli Lilly's EBITDA rose 8427.68% to $8.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 billion, marking a year-over-year increase of 8515.14%. This contributed to the annual value of $16.2 billion for FY2024, which is 5772.93% up from last year.
  • As of Q3 2025, Eli Lilly's EBITDA stood at $8.0 billion, which was up 8427.68% from $7.0 billion recorded in Q2 2025.
  • Eli Lilly's EBITDA's 5-year high stood at $8.0 billion during Q3 2025, with a 5-year trough of $1.4 billion in Q2 2021.
  • Over the past 5 years, Eli Lilly's median EBITDA value was $2.6 billion (recorded in 2022), while the average stood at $3.3 billion.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 3777.97% in 2023, then surged by 10106.13% in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's EBITDA stood at $2.4 billion in 2021, then decreased by 11.82% to $2.1 billion in 2022, then skyrocketed by 44.97% to $3.0 billion in 2023, then skyrocketed by 77.32% to $5.3 billion in 2024, then skyrocketed by 50.27% to $8.0 billion in 2025.
  • Its EBITDA was $8.0 billion in Q3 2025, compared to $7.0 billion in Q2 2025 and $5.3 billion in Q1 2025.